Nuvig: bringing immune homeostasis to inflammatory disease with a $47M A round

Nuvig, which debuted Wednesday with a $47 million series A, believes its protein therapeutics can change how inflammatory and autoimmune diseases are managed by selectively dialing down inflammatory pathways that are already activated, instead of globally suppressing the immune system’s capacity to respond to new threats.

“In the autoimmune disease space, there’s a need for safe and efficacious therapies that don’t inhibit the ability of the immune cells to activate and respond to a pathogen the way that current therapies such as steroids do,” Nuvig Therapeutics Inc. co-founder and CEO Pamela Conley told BioCentury. ...